vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Beats Expectations By $0.51 EPS

vTv Therapeutics (NASDAQ:VTVT) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.51, FiscalAI reports. The firm had revenue of ($0.02) million for the quarter.

vTv Therapeutics Price Performance

VTVT stock opened at $35.10 on Thursday. vTv Therapeutics has a 1 year low of $14.00 and a 1 year high of $44.00. The company has a market cap of $138.29 million, a P/E ratio of -10.48 and a beta of 0.44. The stock’s fifty day moving average price is $36.18 and its 200-day moving average price is $29.26.

Analyst Upgrades and Downgrades

VTVT has been the topic of several analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a research report on Wednesday. Wall Street Zen upgraded vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Evercore assumed coverage on vTv Therapeutics in a report on Thursday. They set an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $47.00 price objective (up from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Finally, TD Cowen began coverage on shares of vTv Therapeutics in a research note on Monday, January 5th. They set a “buy” rating on the stock. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.25.

Hedge Funds Weigh In On vTv Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Baker BROS. Advisors LP boosted its stake in shares of vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after acquiring an additional 51,000 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after acquiring an additional 12,896 shares during the last quarter. 683 Capital Management LLC purchased a new stake in shares of vTv Therapeutics in the fourth quarter worth about $731,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of vTv Therapeutics in the fourth quarter valued at $221,000. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.